Global necrotic enteritis treatment demand is anticipated to be valued at US$ 25 Billion in 2022, forecast to grow at a CAGR of 7.18% to be valued at US$ 50 Billion from 2022 to 2032.
| Report Attribute | Details |
| Estimated Base Year Value (2021) | US$ 20 Billion |
| Expected Market Value (2022) | US$ 25 Billion |
| Anticipated Forecast Value (2032) | US$ 50 Billion |
| Projected Growth Rate (2022-2032) | 7.18% CAGR |
Necrotic enteritis, also known as necrotizing enterocolitis, is an inflammatory bowel disease that affects prematurely born babies. Premature infants are those who are born before 37 weeks of pregnancy. According to the World Health Organization (WHO), approximately 15 million premature babies are born worldwide each year, with the number steadily increasing, and approximately 1 million babies die as a result of this condition.
India has the highest number of preterm births, followed by China, Nigeria, Pakistan, Indonesia, the United States, Bangladesh, the Philippines, Congo, and Brazil. Although the causes of necrotic enteritis are unknown, in December 2018, researchers at Johns Hopkins University School of Medicine discovered the molecular cause of the condition, which is likely to be related to brain injury.
Necrotic enteritis is more likely to occur in prematurely born infants who have been infected. Necrotic enteritis affects 10–12% of prematurely born infants and the majority of cases result in death.
The rising prevalence of preterm births in both developed and developing countries remains a major market driving factor in the necrotic enteritis treatment market. Increased access to good healthcare, increased awareness, and medical attention to pregnancy-related complications all contribute to an increase in treatment-seeking, which drives the growth of the necrotic enteritis treatment market.
The necrotic enteritis treatment market is heavily influenced by ongoing research to identify a causative factor, and breakthrough results may significantly increase revenue generation in the near future. Increased funding for research and development in the necrotic enteritis treatment market by probiotic manufacturing companies is expected to fuel market growth.
The time-consuming nature of developing new breakthrough treatments may impede the growth of the necrotic enteritis treatment market. The unknown cause of necrotic enteritis further limits treatment options, which are frequently ineffective, limiting necrotic enteritis treatment revenue generation.
Because of the high prevalence of preterm births in the region, Asia-Pacific is expected to be the second most lucrative necrotic enteritis treatment market. India and China are among the countries with the highest number of preterm births per year, which can have a significant impact on the necrotic enteritis treatment market.
Although the incidence of preterm birth is higher in the APAC region, a low rate of treatment seeking and product adoption limit the potential revenue generation of the necrotic enteritis treatment market.
According to Future Market Insights, Because of the higher treatment seeking rate, the global necrotic enteritis treatment market is expected to be dominated by the North American necrotic enteritis treatment market.
Prometic Life Sciences Inc., BioGaia Probiotics, Fresenius Kabi AG, Actavis Plc. Bayer International, Alcon Laboratories, Inc., Bausch & Lomb Incorporated, GlaxoSmithKline plc. and Others are the key players in the global necrotic enteritis treatment market.
Attributed to the presence of such high number of participants, the market is highly competitive.
| Report Attribute | Details |
| Growth Rate | CAGR of 7.18% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015-2020 |
| Forecast Period | 2022-2032 |
| Quantitative Units | Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
By Drug Class:
By Distribution Channel:
By Region:
FMI projects the global Necrotic Enteritis Treatment market to expand at a 7.18% value CAGR by 2032
North America is expected to be the most opportunistic necrotic enteritis treatment market
Prometic Life Sciences Inc., BioGaia Probiotics, Fresenius Kabi AG, Actavis Plc., and Bayer International, are some prominent Necrotic Enteritis Treatment manufacturers
Explore Similar Insights
Necrotic Enteritis Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
